Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1983 1
1985 1
1994 1
1998 1
2000 3
2001 3
2002 6
2003 5
2004 8
2005 14
2006 17
2007 4
2008 18
2009 13
2010 13
2011 13
2012 21
2013 13
2014 18
2015 18
2016 16
2017 23
2018 25
2019 24
2020 31
Text availability
Article attribute
Article type
Publication date

Search Results

293 results
Results by year
Filters applied: . Clear all
Page 1
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. O'Mahony L, et al. Gastroenterology. 2005 Mar;128(3):541-51. doi: 10.1053/j.gastro.2004.11.050. Gastroenterology. 2005. PMID: 15765388 Clinical Trial.
BACKGROUND & AIMS: The aim of this study was to compare the response of symptoms and cytokine ratios in irritable bowel syndrome (IBS) with ingestion of probiotic preparations containing a lactobacillus or bifidobacterium strain. ...RESULTS: For al …
BACKGROUND & AIMS: The aim of this study was to compare the response of symptoms and cytokine ratios in irritable bowel
Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.
Ducrotté P, Sawant P, Jayanthi V. Ducrotté P, et al. World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012. World J Gastroenterol. 2012. PMID: 22912552 Free PMC article. Clinical Trial.
AIM: To assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) (DSM 9843) for the relief of abdominal symptoms in a large subset of irritable bowel syndrome (IBS) patients fulfilling the Rome III criteria. ...
AIM: To assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) (DSM 9843) for the relief of abdominal sy …
Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial.
Sadrin S, Sennoune SR, Gout B, Marque S, Moreau J, Grillasca J, Pons O, Maixent JM. Sadrin S, et al. Cell Mol Biol (Noisy-le-grand). 2017 Sep 30;63(9):122-131. doi: 10.14715/cmb/2017.63.9.21. Cell Mol Biol (Noisy-le-grand). 2017. PMID: 28980935 Clinical Trial.
Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by abdominal pain/discomfort and altered bowel habits. ...The current clinical trial protocol aims to determine the effects of a mixture of Lactobacillus ac
Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by abdominal pain/discomfort a
Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
Lyra A, Hillilä M, Huttunen T, Männikkö S, Taalikka M, Tennilä J, Tarpila A, Lahtinen S, Ouwehand AC, Veijola L. Lyra A, et al. World J Gastroenterol. 2016 Dec 28;22(48):10631-10642. doi: 10.3748/wjg.v22.i48.10631. World J Gastroenterol. 2016. PMID: 28082816 Free PMC article. Clinical Trial.
AIM: To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL). ...
AIM: To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS) symptoms and q …
Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids.
Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Han X, et al. Gut Microbes. 2019;10(1):59-76. doi: 10.1080/19490976.2018.1479625. Epub 2018 Aug 6. Gut Microbes. 2019. PMID: 30040527 Free PMC article.
Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndrome (IBS). Lactobacillus rhamnosus GG (LGG) improves IBS symptoms through unclear mechanisms. Previous studies utilizing colorecta …
Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndro
Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis.
Liang D, Longgui N, Guoqiang X. Liang D, et al. Medicine (Baltimore). 2019 Jul;98(27):e16068. doi: 10.1097/MD.0000000000016068. Medicine (Baltimore). 2019. PMID: 31277101 Free PMC article.
BACKGROUND: Probiotics is a prevalence therapeutic method for irritable bowel syndrome (IBS), but there is lack of comparison in different protocols. ...The protocols with suitable dose combined of Lactobacillus and Bifidobacterium can have prepotent e …
BACKGROUND: Probiotics is a prevalence therapeutic method for irritable bowel syndrome (IBS), but there is lack of comp …
Probiotics for Gastrointestinal Conditions: A Summary of the Evidence.
Wilkins T, Sequoia J. Wilkins T, et al. Am Fam Physician. 2017 Aug 1;96(3):170-178. Am Fam Physician. 2017. PMID: 28762696 Free article. Review.
The most-studied species include Lactobacillus, Bifidobacterium, and Saccharomyces. However, a lack of clear guidelines on when to use probiotics and the most effective probiotic for different gastrointestinal conditions may be confusing for family physicians and their pat …
The most-studied species include Lactobacillus, Bifidobacterium, and Saccharomyces. However, a lack of clear guidelines on when to us …
Thirty Years of Lactobacillus rhamnosus GG: A Review.
Capurso L. Capurso L. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. doi: 10.1097/MCG.0000000000001170. J Clin Gastroenterol. 2019. PMID: 30741841 Review.
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. ...The effectiveness
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to it
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Giannetti E, Staiano A. Giannetti E, et al. J Pediatr Gastroenterol Nutr. 2016 Jul;63 Suppl 1:S25-6. doi: 10.1097/MPG.0000000000001220. J Pediatr Gastroenterol Nutr. 2016. PMID: 27380595 Review.
A meta-analysis including 9 trials which tested different probiotics as a treatment for Functional Gastrointestinal Disorders (FGIDs) in children and adolescents concluded that Lactobacillus GG, Lactobacillus reuteri DSM 17938 and VSL#3 significantly increased treat …
A meta-analysis including 9 trials which tested different probiotics as a treatment for Functional Gastrointestinal Disorders (FGIDs) in chi …
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Currò D, et al. Br J Pharmacol. 2017 Jun;174(11):1426-1449. doi: 10.1111/bph.13632. Epub 2016 Oct 25. Br J Pharmacol. 2017. PMID: 27696378 Free PMC article. Review.
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. ...Probiotics, in particular Saccharomyces boulardii and Lactobacilli (amo …
Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also ca …
293 results
Jump to page
Feedback